Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. (Q40184010)
Jump to navigation
Jump to search
scientific article published on 11 January 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. |
scientific article published on 11 January 2007 |
Statements
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation (English)
Deborah L Marrocco
Andreas Evdokiou
Howard I Scher
Richard A Rifkind
Paul A Marks
Victoria M Richon
Lisa M Butler
11 January 2007